Results 231 to 237 of about 21,799 (237)

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

Arthritis and Rheumatology, 2018
Frank H J Van Den Hoogen, Alfons A Den Broeder   +1 more
exaly  

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

Arthritis and Rheumatology, 2018
Michael E Weinblatt
exaly  

Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars

Nature Reviews Drug Discovery, 2012
John R Engen
exaly  

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

BioDrugs, 2019
Isabelle Huys, Arnold G Vulto, Steven R A Simoens   +2 more
exaly  

Analytical characterization of biosimilar antibodies and Fc-fusion proteins

TrAC - Trends in Analytical Chemistry, 2013
Alain Beck, Daniel Ayoub, Christine Carapito   +2 more
exaly  

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Journal of Internal Medicine, 2019
exaly  

Biosimilar

Ya Wang, Qinqin Xu, Xiangyu Zhang
openaire   +1 more source